Have a question?
Please get in touch with our team in case of any queries
THE BIOMARKERS MARKET SIZE WAS VALUED AT USD 45.11 BILLION IN 2021 AND IS EXPECTED TO REACH USD 86.41 BILLION BY 2027, GROWING AT A CAGR OF 11.44% DURING THE FORECAST PERIOD.
Biomarkers Market Share, Size Trends Analysis, by-
- Indication: Oncology, Cardiology, Neurology, Immunology, and Others
- Application: Diagnostics, Drug Discovery & Development, Personalized Medicine (PM), and Others
- Type: Diagnostic Biomarker, Monitoring Biomarker, Prognostic Biomarker, Susceptibility Biomarker, and Other Biomarker
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
BIOMARKERS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| MARKET SIZE (2027) | USD 86.41 BILLION |
| MARKET SIZE (2021) | USD 45.11 BILLION |
| CAGR (2022-2027) | 11.41% |
| FASTEST GROWING REGION | Asia-Pacific |
| MARKET SEGMENTS | Indication (Oncology, Cardiology, Neurology, Immunology and Others), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine (PM), and Others), Type (Diagnostic Biomarker, Monitoring Biomarker, Prognostic Biomarker, Susceptibility Biomarker, and Other Biomarker) |
| REGION WITH HIGHEST SHARE | NORTH AMERICA |
| GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
| COUNTRIES COVERED | US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, Argentina, Turkey, South Africa, Saudi Arabia |
BIOMARKERS MARKET OVERVIEW
The biomarkers market size was valued at USD 45.11 billion in 2021 and is expected to reach USD 86.41 billion by 2027, growing at a CAGR of 11.44% during the forecast period.
Increasing adoption of biomarkers in personalized medicine and a growing focus on digital biomarkers fuel market growth. Biomarkers are increasingly valuable tools for predicting prognosis and therapy response in cancer patients. Furthermore, it allows for improving understanding of mechanisms of action and resistance to treatment. It is a rapidly advancing area in autoimmune disease. Various researchers have been working on discovering new biomarkers, including autoantibodies in autoimmune diseases.
Vendors are focusing on increasing biomarker discoveries and biomarker-based diagnostics development because of the high demand in diagnostics for personalized medicine and drug discovery and development. The vendor’s focus is on fitting treatments to patients; providing the right therapy for the right group of people at the right time is increasing the demand for biomarkers research.
KEY HIGHLIGHTS
- Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focussing on identifying biomarkers to provide healthcare system solutions to them.
- Increasing focus on digital biomarkers will also drive the global Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinson’s and Alzheimer's disease and clinical outcome assessments.
- Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. More emerging companies are increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers.
- Technological Advancements in genomic biomarker discovery also positively impact the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.
BIOMARKERS MARKET SEGMENTATION
- In 2021, the oncology segment accounted for more than 30% of the global market share. Biomarkers are highly in use in cancer research and medicine. Now, physicians are increasingly using cancer biomarkers to gain more information about a patient's tumor to predict the treatment that is most likely to work against their unique cancer.
- By application, the diagnostics segment will lead in the biomarkers industry. Biomarkers are critical to the rational development of medical diagnostics and therapeutics. Complex composite and digital biomarkers derived from sensors and mobile technologies and biomarker-driven predictive toxicology and systems pharmacology are reshaping the development of diagnostic and therapeutic technologies in the genomic biomarkers market.
- The diagnostic biomarkers market segment will witness the highest growth. Many diseases have subtypes with markedly different prognoses or responses to a specific treatment. Diagnostic biomarkers that identify disease subtypes thus often play critical roles when the results of diagnostic classification are used as prognostic biomarkers and predictive biomarkers.
GEOGRAPHICAL ANALYSIS
- North America: North America accounted for the highest share of the biomarkers market. Personalized medicine is rapidly increasing attention in North America with the increasing number of projects and funds. In recent years, the FDA has expanded its approval in new gene therapy for treating a rare disease; and has also qualified the first digital technology platform via its pre-certification program. There are also opportunities coming up in the future to adopt more advanced technologies in the US, such as digital biomarkers, to make disease management more effortless.
- APAC: APAC region had the highest growth rate among all regions in the biomarkers industry. High-income countries such as China, Japan, and Australia have been the top sharers of biomarkers in the APAC region. The biomarker market in India and South Korea is driven by rising medical costs of treatments, chronic illness, and an aging population. The south Korean precision medicine market is predicted to grow strongly over ten years. In recent years, South Korea has started making huge investments in the development of personalized medicine, using big data to foster start-up companies in the biotech industry in the upcoming years.
VENDOR LANDSCAPE
- The major players in the market are Abbott company, BioMerieux, Biohit OYJ, CENTOGENE, Creative Diagnostics, Hoffmann-La Roche company, Fujirebio, and General Electric (GE) company, and TAmiRNA.
- Vendors also need to develop new product launches providing enough clinical trial data to get easy approval from regulatory bodies.
- Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.
- Vendors need to strategically focus on inorganic growth through mergers and acquisitions, increasing the collaborations with various research organizations academic, and also bringing out initiatives socio-economically to raise the awareness
The biomarkers market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
Segmentation by Indication
- Oncology
- Cardiology
- Neurology
- Immunology
- Others
Segmentation by Application
- Diagnostics
- Drug Discovery & Development
- Personalized Medicine (PM)
- Others
Segmentation by Type
- Diagnostic Biomarker
- Monitoring Biomarker
- Prognostic Biomarker
- Susceptibility Biomarker
- Other Biomarker
Segmentation by Geography
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- APAC
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
SNAPSHOT
The biomarkers market was valued at USD 45.11 billion in 2021 and is expected to reach USD 86.41 billion by 2027, growing at a CAGR of 11.44% during the forecast period
The following factors are likely to contribute to the growth of the biomarkers market-
- Increased Adoption of Biomarkers in Personalized Medicine
- Increasing Focus on Digital Biomarkers
- Increasing Discovery of Epigenetic Biomarkers for Oncology
- Increase in Number of Pipeline Biomarkers
- Rising Adoption of Biomarkers in Disease Diagnostics
Base Year: 2021
Forecast Year: 2022-2027
The study considers a detailed scenario of the present biomarkers market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
KEY VENDORS
- Abbott company
- BioMerieux
- Biohit OYJ
- CENTOGENE
- Creative Diagnostics
- F. Hoffmann-La Roche company
- Fujirebio
- General Electric (GE) company
- TAmiRNA
Other Prominent Vendors
- Accure Therapeutics
- Agilent
- Almac Group
- Applied Research Using OMIC Sciences (AROMICS)
- Bio-Rad Laboratories
- BioVision
- Caris Life Sciences
- Denovo Biopharma
- Dreamgenics
- Eisai
- Epigenomics
- Immunovia
- Insilico Medicine
- Lexogen
- Monument Tx
- Oryzon Genomics
- Plexision
- Rules-Based Medicine
- Siemens Healthineers
- Second Genome Therapeutics
- Thermo Fisher Scientific
- Ymir Genomics
Segmentation by Indication
- Oncology
- Cardiology
- Neurology
- Immunology
- Others
Segmentation by Application
- Diagnostics
- Drug Discovery & Development
- Personalized Medicine (PM)
- Others
Segmentation by Type
- Diagnostic Biomarker
- Monitoring Biomarker
- Prognostic Biomarker
- Susceptibility Biomarker
- Other Biomarker
Segmentation by Geography
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- APAC
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
Frequently Asked Questions
What is the current size of the global biomarkers market?
Who are the leading players in the biomarkers market?
What are the major drivers of the biomarkers market?
Which region has the highest share in the industry?
Which application segment is leading in the biomarkers industry?
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL BIOMARKERS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 OVERVIEW OF BIOMARKER DEVELOPMENT PROCESS
EXHIBIT 4 VARIOUS ORGANIZATIONAL STRUCTURES PREVALENT AMONG BIOMARKER DISCOVERY ORGANIZATIONS (PERCENT OF TOP-20 PHARMACEUTICAL COMPANIES)
EXHIBIT 5 IMPACT OF INCREASED ADOPTION OF BIOMARKERS IN PERSONALIZED MEDICINE
EXHIBIT 6 NUMBER OF APPROVALS OF BIOMARKER-DRIVEN PERSONALIZED MEDICINE 2008-2018
EXHIBIT 7 COMPANION DIAGNOSTICS PIPELINE IN PERSONALIZED MEDICINE
EXHIBIT 8 IMPACT OF INCREASING FOCUS ON DIGITAL BIOMARKERS
EXHIBIT 9 IMPACT OF INCREASING DISCOVERY OF EPIGENETIC BIOMARKERS IN ONCOLOGY
EXHIBIT 10 IMPACT OF INCREASE IN THE NUMBER OF PIPELINE BIOMARKERS
EXHIBIT 11 IMPACT OF RISING ADOPTION OF BIOMARKERS IN DISEASE DIAGNOSTICS
EXHIBIT 12 IMPACT OF TECHNOLOGICAL ADVANCEMENTS IN BIOMARKER DISCOVERY
EXHIBIT 13 IMPACT OF HIGH COST AND TIME-CONSUMING DEVELOPMENT
EXHIBIT 14 BIOMARKER IDENTIFICATION, DEVELOPMENT, AND VALIDATION LIFECYCLE
EXHIBIT 15 GENERAL COST RANGE BY BIOMARKER CATEGORY
EXHIBIT 16 IMPACT OF HIGH NUMBER OF FALSE DISCOVERIES
EXHIBIT 17 IMPACT OF STRICT REGULATIONS AND ETHICS FOR BIOMARKER VALIDATION & QUALIFICATION
EXHIBIT 18 GLOBAL BIOMARKERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 19 GLOBAL BIOMARKERS MARKET SHARE BY INDICATION 2021 & 2027 (%)
EXHIBIT 20 GLOBAL BIOMARKERS MARKET SHARE BY APPLICATION 2021 & 2027 (%)
EXHIBIT 21 GLOBAL BIOMARKERS MARKET SHARE BY TYPE 2021 & 2027 (%)
EXHIBIT 22 GLOBAL BIOMARKERS MARKET SHARE BY GEOGRAPHY 2021 & 2027 (%)
EXHIBIT 23 FIVE FORCES ANALYSIS 2021
EXHIBIT 24 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 25 GLOBAL BIOMARKERS MARKET BY INDICATION
EXHIBIT 26 GLOBAL BIOMARKERS MARKET BY INDICATION – INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 27 GLOBAL BIOMARKERS ONCOLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 GLOBAL BIOMARKERS ONCOLOGY MARKET 2021–2027 ($ BILLION)
EXHIBIT 29 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 30 GLOBAL BIOMARKERS CARDIOLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 31 GLOBAL BIOMARKERS CARDIOLOGY MARKET 2021–2027 ($ BILLION)
EXHIBIT 32 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 33 GLOBAL BIOMARKERS NEUROLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL BIOMARKERS NEUROLOGY MARKET 2021–2027 ($ BILLION)
EXHIBIT 35 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 36 GLOBAL BIOMARKERS IMMUNOLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL BIOMARKERS IMMUNOLOGY MARKET 2021–2027 ($ BILLION)
EXHIBIT 38 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 39 GLOBAL BIOMARKERS OTHER INDICATIONS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 40 GLOBAL BIOMARKERS OTHER INDICATIONS MARKET 2021–2027 ($ BILLION)
EXHIBIT 41 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 42 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 43 GLOBAL BIOMARKERS MARKET BY APPLICATION
EXHIBIT 44 GLOBAL BIOMARKERS MARKET BY APPLICATION – INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 45 GLOBAL BIOMARKERS MARKET BY APPLICATION – ABSOLUTE GROWTH (%)
EXHIBIT 46 TYPES OF BIOMARKERS LIKELY TESTED FOR DIAGNOSIS OF CANCER IN THE US BY 2018
EXHIBIT 47 GLOBAL BIOMARKERS DIAGNOSTICS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL BIOMARKERS DIAGNOSTICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 49 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 50 GLOBAL BIOMARKERS DRUG DISCOVERY & DEVELOPMENT MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 DRUG DISCOVERY & DEVELOPMENT PROCESSES WITH THE POTENTIAL TO BENEFIT FROM BIOMARKERS PHASE I, II, AND III
EXHIBIT 52 GLOBAL BIOMARKERS DRUG DISCOVERY & DEVELOPMENT MARKET 2021–2027 ($ BILLION)
EXHIBIT 53 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 54 APPLICATION AREAS OF PM
EXHIBIT 55 GLOBAL BIOMARKERS PERSONALIZED MEDICINE MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL BIOMARKERS PERSONALIZED MEDICINE MARKET 2021–2027 ($ BILLION)
EXHIBIT 57 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 58 GLOBAL BIOMARKERS OTHER APPLICATIONS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL BIOMARKERS OTHER APPLICATIONS MARKET 2021–2027 ($ BILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 61 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 62 GLOBAL BIOMARKERS MARKET BY TYPE
EXHIBIT 63 GLOBAL BIOMARKERS MARKET BY TYPE – INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 64 GLOBAL BIOMARKERS MARKET BY TYPE – ABSOLUTE GROWTH (%)
EXHIBIT 65 GLOBAL DIAGNOSTIC BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 CHROMATIN CONFORMATION: PROGNOSTIC AND PREDICTIVE BIOMARKERS WITH DIAGNOSTIC UTILITY
EXHIBIT 67 GLOBAL DIAGNOSTIC BIOMARKERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 68 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 69 GLOBAL MONITORING BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 70 GLOBAL MONITORING BIOMARKERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 71 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 72 GLOBAL PROGNOSTIC BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 GLOBAL PROGNOSTIC BIOMARKERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 74 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 75 GLOBAL PREDICTIVE BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 76 GLOBAL PREDICTIVE BIOMARKERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 77 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 78 GLOBAL SUSCEPTIBILITY BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 79 GLOBAL SUSCEPTIBILITY BIOMARKERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 80 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 81 SELECTED PHARMACODYNAMICS MARKERS IN TUMOR AND SURROGATE TISSUES
EXHIBIT 82 GLOBAL OTHER BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 83 CURRENT EMERGING SAFETY BIOMARKERS OPPORTUNITIES FOR QUALIFICATION
EXHIBIT 84 PERCENTAGE OF COMPANIES USING EMERGING SAFETY BIOMARKERS IN NONCLINICAL STUDIES
EXHIBIT 85 GLOBAL OTHER BIOMARKERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 86 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 87 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 88 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY
EXHIBIT 89 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY – INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 90 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY – ABSOLUTE GROWTH (%)
EXHIBIT 91 NORTH AMERICA BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 92 NORTH AMERICA BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 93 BIOMARKERS MARKET IN NORTH AMERICA 2021–2027 ($ BILLION)
EXHIBIT 94 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 95 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 96 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 97 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 98 PERSONALIZED MEDICINES WITH SPECIFIC BIOMARKERS – TOP 20% OF FDA APPROVALS 2005-2019
EXHIBIT 99 APPROVED THERAPEUTIC MOLECULAR ENTITIES IN PERSONALIZED MEDICINE IN 2019
EXHIBIT 100 BIOMARKERS MARKET IN THE US 2021–2027 ($ BILLION)
EXHIBIT 101 CIHR PROJECTED LEVERAGE BY PARTNER TYPE FOR PERSONALIZED MEDICINE BUSINESS
EXHIBIT 102 BIOMARKERS MARKET IN CANADA 2021–2027 ($ BILLION)
EXHIBIT 103 EUROPE BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 104 EUROPE BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 105 BIOMARKERS MARKET IN EUROPE 2021–2027 ($ BILLION)
EXHIBIT 106 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 107 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 108 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 109 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 110 BIOMARKERS MARKET IN GERMANY 2021–2027 ($ BILLION)
EXHIBIT 111 BIOMARKERS MARKET IN FRANCE 2021–2027 ($ BILLION)
EXHIBIT 112 BIOMARKERS MARKET IN THE UK 2021–2027 ($ BILLION)
EXHIBIT 113 BIOMARKERS MARKET IN ITALY 2021–2027 ($ BILLION)
EXHIBIT 114 BIOMARKERS MARKET IN SPAIN 2021–2027 ($ BILLION)
EXHIBIT 115 APAC BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 116 APAC BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 117 BIOMARKERS MARKET IN APAC 2021–2027 ($ BILLION)
EXHIBIT 118 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 119 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 120 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 121 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 122 BIOMARKERS MARKET IN JAPAN 2021–2027 ($ BILLION)
EXHIBIT 123 BIOMARKERS MARKET IN CHINA 2021–2027 ($ BILLION)
EXHIBIT 124 BIOMARKERS MARKET IN INDIA 2021–2027 ($ BILLION)
EXHIBIT 125 BIOMARKERS MARKET IN SOUTH KOREA 2021–2027 ($ BILLION)
EXHIBIT 126 BIOMARKERS MARKET IN AUSTRALIA 2021–2027 ($ BILLION)
EXHIBIT 127 LATIN AMERICA BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 128 LATIN AMERICA BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 129 BIOMARKERS MARKET IN LATIN AMERICA 2021–2027 ($ BILLION)
EXHIBIT 130 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 131 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 132 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 133 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 134 BIOMARKERS MARKET IN BRAZIL 2021–2027 ($ BILLION)
EXHIBIT 135 BIOMARKERS MARKET IN MEXICO 2021–2027 ($ BILLION)
EXHIBIT 136 BIOMARKERS MARKET IN ARGENTINA 2021–2027 ($ BILLION)
EXHIBIT 137 MIDDLE EAST & AFRICA BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 138 MIDDLE EAST & AFRICA BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 139 BIOMARKERS MARKET IN THE MIDDLE EAST & AFRICA 2021–2027 ($ BILLION)
EXHIBIT 140 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 141 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 142 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 143 INCREMENTAL GROWTH IN THE MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 144 BIOMARKERS MARKET IN TURKEY 2021–2027 ($ BILLION)
EXHIBIT 145 BIOMARKERS MARKET IN SOUTH AFRICA 2021–2027 ($ BILLION)
EXHIBIT 146 BIOMARKERS MARKET IN SAUDI ARABIA 2021–2027 ($ BILLION)
EXHIBIT 147 ABBOTT: TOTAL REVENUE 2018-2020 ($ BILLION)
EXHIBIT 148 ABBOTT: R&D EXPENDITURE 2018-2020 ($ BILLION)
EXHIBIT 149 BIOMÉRIEUX: R&D EXPENDITURE 2018-2020 ($ BILLION)
EXHIBIT 150 BIOMÉRIEUX: TOTAL REVENUE 2018-2020 ($ BILLION)
EXHIBIT 151 BIOHIT OYJ: TOTAL REVENUE 2018-2020 ($ BILLION)
EXHIBIT 152 BIOHIT OYJ: MARKET SHARE BY GEOGRAPHY (2020)
EXHIBIT 153 CENTOGENE: TOTAL REVENUE 2018-2020 ($ BILLION)
EXHIBIT 154 CENTOGENE: R&D EXPENDITURE 2018-2020 ($ BILLION)
EXHIBIT 155 CENTOGENE: REVENUE BY PHARMACEUTICAL SEGMENT 2018-2020 ($ BILLION)
EXHIBIT 156 CENTOGENE: MARKET SHARE BY GEOGRAPHY (2020)
EXHIBIT 157 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2018-2020 ($ BILLION)
EXHIBIT 158 GE HEALTHCARE: TOTAL REVENUE 2018-2020 ($ BILLION)
EXHIBIT 159 GE HEALTHCARE: MARKET SHARE OF HEALTHCARE SEGMENT BY GEOGRAPHY (2020)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 TYPES OF BIOMARKERS
TABLE 4 PIPELINE BIOMARKERS
TABLE 5 PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM SALIVA
TABLE 6 SUMMARY OF PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM SWEAT
TABLE 7 SUMMARY OF PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM BLOOD
TABLE 8 SUMMARY OF PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM TEARS/BREATH
TABLE 9 TIME FRAME FOR BIOMARKER DEVELOPMENT
TABLE 10 AVERAGE COST RANGES FOR PREDICTIVE BIOMARKERS AND CLINICAL TRIAL ENDPOINTS BY PHASE OF BIOMARKER DEVELOPMENT
TABLE 11 ORIGINS OF 165 FALSE POSITIVE BIOMARKERS OBTAINED
TABLE 12 PROBLEMS AT EACH STAGE OF THE BIOMARKER RESEARCH PIPELINE
TABLE 13 STEPS IN FDA BIOMARKER QUALIFICATION PROGRAM PROCEDURE
TABLE 14 BIOSENSORS FOR IMPROVED DETECTION OF DIAGNOSTIC BIOMARKERS FROM VARIOUS SOURCES
TABLE 15 METHYLATION: PROGNOSTIC AND PREDICTIVE BIOMARKERS WITH DIAGNOSTIC ABILITY
TABLE 16 HISTONE MODIFICATIONS: PROGNOSTIC & PREDICTIVE BIOMARKERS WITH DIAGNOSTIC UTILITY
TABLE 17 MICRORNA: PROGNOSTIC AND PREDICTIVE BIOMARKERS WITH DIAGNOSTIC UTILITY
TABLE 18 EXAMPLES OF SUCCESSFULLY DEVELOPED PREDICTIVE BIOMARKERS IN MODERN ONCOLOGY
TABLE 19 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 20 BIOMÉRIEUX: MAJOR PRODUCT OFFERINGS
TABLE 21 BIOHIT OYJ: MAJOR PRODUCT OFFERINGS
TABLE 22 CENTOGENE: MAJOR PRODUCT OFFERINGS
TABLE 23 CREATIVE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 24 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 25 FUJIREBIO: MAJOR PRODUCT OFFERINGS
TABLE 26 GE HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 27 TAMIRNA: MAJOR PRODUCT OFFERINGS
TABLE 28 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 29 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 30 GLOBAL BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)
TABLE 31 GLOBAL BIOMARKERS MARKET BY INDICATION 2021−2027 (%)
TABLE 32 GLOBAL BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)
TABLE 33 GLOBAL BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)
TABLE 34 GLOBAL BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)
TABLE 35 GLOBAL BIOMARKERS MARKET BY TYPE 2021−2027 (%)
TABLE 36 NORTH AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)
TABLE 37 NORTH AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 (%)
TABLE 38 NORTH AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)
TABLE 39 NORTH AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)
TABLE 40 NORTH AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)
TABLE 41 NORTH AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 (%)
TABLE 42 EUROPE BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)
TABLE 43 EUROPE BIOMARKERS MARKET BY INDICATION 2021−2027 (%)
TABLE 44 EUROPE BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)
TABLE 45 EUROPE BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)
TABLE 46 EUROPE BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)
TABLE 47 EUROPE BIOMARKERS MARKET BY TYPE 2021−2027 (%)
TABLE 48 APAC BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)
TABLE 49 APAC BIOMARKERS MARKET BY INDICATION 2021−2027 (%)
TABLE 50 APAC BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)
TABLE 51 APAC BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)
TABLE 52 APAC BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)
TABLE 53 APAC BIOMARKERS MARKET BY TYPE 2021−2027 (%)
TABLE 54 LATIN AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)
TABLE 55 LATIN AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 (%)
TABLE 56 LATIN AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)
TABLE 57 LATIN AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)
TABLE 58 LATIN AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)
TABLE 59 LATIN AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 (%)
TABLE 60 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)
TABLE 61 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY INDICATION 2021−2027 (%)
TABLE 62 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)
TABLE 63 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)
TABLE 64 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)
TABLE 65 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY TYPE 2021−2027 (%)
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.4 MARKET SEGMENTS
4.4.1 MARKET SEGMENTATION BY INDICATION
4.4.2 MARKET SEGMENTATION BY APPLICATION
4.4.3 MARKET SEGMENTATION BY TYPE
4.4.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
8 MARKET OPPORTUNITIES & TRENDS
8.1 INCREASED ADOPTION OF BIOMARKERS IN PERSONALIZED MEDICINE
8.2 INCREASING FOCUS ON DIGITAL BIOMARKERS
8.3 INCREASED DISCOVERY OF EPIGENETIC BIOMARKERS IN ONCOLOGY
9 MARKET GROWTH ENABLERS
9.1 INCREASE IN THE NUMBER OF PIPELINE BIOMARKERS
9.2 RISING ADOPTION OF BIOMARKERS IN DISEASE DIAGNOSTICS
9.3 TECHNOLOGICAL ADVANCEMENTS IN BIOMARKER DISCOVERY
10 MARKET RESTRAINTS
10.1 HIGH COST AND TIME-CONSUMING DEVELOPMENT
10.2 HIGH NUMBER OF FALSE DISCOVERIES
10.3 STRICT REGULATIONS AND ETHICS FOR BIOMARKER VALIDATION & QUALIFICATION
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 INSIGHTS BY INDICATION
11.2.2 INSIGHTS BY APPLICATION
11.2.3 INSIGHTS BY TYPE
11.2.4 INSIGHTS BY GEOGRAPHY
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 INDICATION
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 ONCOLOGY
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 MARKET BY GEOGRAPHY
12.4 CARDIOLOGY
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 MARKET BY GEOGRAPHY
12.5 NEUROLOGY
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 MARKET BY GEOGRAPHY
12.6 IMMUNOLOGY
12.6.1 MARKET OVERVIEW
12.6.2 MARKET SIZE & FORECAST
12.6.3 MARKET BY GEOGRAPHY
12.7 OTHERS
12.7.1 MARKET OVERVIEW
12.7.2 MARKET SIZE & FORECAST
12.7.3 MARKET BY GEOGRAPHY
13 APPLICATION
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 DIAGNOSTICS
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 DRUG DISCOVERY & DEVELOPMENT
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
13.5 PERSONALIZED MEDICINE
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 MARKET BY GEOGRAPHY
13.6 OTHERS
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
13.6.3 MARKET BY GEOGRAPHY
14 TYPE
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 DIAGNOSTIC BIOMARKERS
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 MONITORING BIOMARKERS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 PROGNOSTIC BIOMARKERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 PREDICTIVE BIOMARKERS
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
14.7 SUSCEPTIBILITY BIOMARKERS
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 MARKET BY GEOGRAPHY
14.8 OTHER BIOMARKERS
14.8.1 MARKET OVERVIEW
14.8.2 MARKET SIZE & FORECAST
14.8.3 MARKET BY GEOGRAPHY
15 GEOGRAPHY
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 GEOGRAPHIC OVERVIEW
16 NORTH AMERICA
16.1 MARKET OVERVIEW
16.2 MARKET SIZE & FORECAST
16.3 NORTH AMERICA: TYPE
16.4 NORTH AMERICA: APPLICATION
16.5 NORTH AMERICA: INDICATION
16.6 KEY COUNTRIES
16.6.1 US: MARKET SIZE & FORECAST
16.6.2 CANADA: MARKET SIZE & FORECAST
17 EUROPE
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 EUROPE: TYPE
17.4 EUROPE: APPLICATION
17.5 EUROPE: INDICATION
17.6 KEY COUNTRIES
17.6.1 GERMANY: MARKET SIZE & FORECAST
17.6.2 FRANCE: MARKET SIZE & FORECAST
17.6.3 UK: MARKET SIZE & FORECAST
17.6.4 ITALY: MARKET SIZE & FORECAST
17.6.5 SPAIN: MARKET SIZE & FORECAST
18 APAC
18.1 MARKET OVERVIEW
18.2 APAC: TYPE
18.3 APAC: APPLICATION
18.4 APAC: INDICATION
18.5 KEY COUNTRIES
18.5.1 JAPAN: MARKET SIZE & FORECAST
18.5.2 CHINA: MARKET SIZE & FORECAST
18.5.3 INDIA: MARKET SIZE & FORECAST
18.5.4 SOUTH KOREA: MARKET SIZE & FORECAST
18.5.5 AUSTRALIA: MARKET SIZE & FORECAST
19 LATIN AMERICA
19.1 MARKET OVERVIEW
19.2 LATIN AMERICA: TYPE
19.3 LATIN AMERICA: APPLICATION
19.4 LATIN AMERICA: INDICATION
19.5 KEY COUNTRIES
19.5.1 BRAZIL: MARKET SIZE & FORECAST
19.5.2 MEXICO: MARKET SIZE & FORECAST
19.5.3 ARGENTINA: MARKET SIZE & FORECAST
20 MIDDLE EAST & AFRICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORRECAST
20.3 MIDDLE EAST & AFRICA: TYPE
20.4 MIDDLE EAST & AFRICA: APPLICATION
20.5 MIDDLE EAST & AFRICA: INDICATION
20.6 KEY COUNTRIES
20.6.1 TURKEY: MARKET SIZE & FORECAST
20.6.2 SOUTH AFRICA: MARKET SIZE & FORECAST
20.6.3 SAUDI ARABIA: MARKET SIZE & FORECAST
21 COMPETITIVE LANDSCAPE
21.1 COMPETITION OVERVIEW
21.2 MARKET SHARE ANALYSIS
21.2.1 ABBOTT
21.2.2 BIOMÉRIEUX
21.2.3 BIOHIT OYJ
21.2.4 CENTOGENE
21.2.5 CREATIVE DIAGNOSTICS
21.2.6 GE HEALTHCARE
21.2.7 ROCHE
21.2.8 TAMIRNA
21.2.9 FUJIREBIO
22 KEY COMPANY PROFILES
22.1 ABBOTT
22.1.1 BUSINESS OVERVIEW
22.1.2 MAJOR PRODUCT OFFERINGS
22.1.3 KEY STRATEGIES
22.1.4 KEY STRENGTHS
22.1.5 KEY OPPORTUNITIES
22.2 BIOMÉRIEUX
22.2.1 BUSINESS OVERVIEW
22.2.2 MAJOR PRODUCT OFFERINGS
22.2.3 KEY STRATEGIES
22.2.4 KEY STRENGTHS
22.2.5 KEY OPPORTUNITIES
22.3 BIOHIT OYJ
22.3.1 BUSINESS OVERVIEW
22.3.2 MAJOR PRODUCT OFFERINGS
22.3.3 KEY STRATEGIES
22.3.4 KEY STRENGTHS
22.3.5 KEY OPPORTUNITIES
22.4 CENTOGENE
22.4.1 BUSINESS OVERVIEW
22.4.2 MAJOR PRODUCT OFFERINGS
22.4.3 KEY STRATEGIES
22.4.4 KEY STRENGTHS
22.4.5 KEY OPPORTUNITIES
22.5 CREATIVE DIAGNOSTICS
22.5.1 BUSINESS OVERVIEW
22.5.2 MAJOR PRODUCT OFFERINGS
22.5.3 KEY STRATEGIES
22.5.4 KEY STRENGTHS
22.5.5 KEY OPPORTUNITIES
22.6 F. HOFFMANN-LA ROCHE
22.6.1 BUSINESS OVERVIEW
22.6.2 MAJOR PRODUCT OFFERINGS
22.6.3 KEY STRATEGIES
22.6.4 KEY STRENGTHS
22.6.5 KEY OPPORTUNITIES
22.7 FUJIREBIO
22.7.1 BUSINESS OVERVIEW
22.7.2 MAJOR PRODUCT OFFERINGS
22.7.3 KEY STRATEGIES
22.7.4 KEY STRENGTHS
22.7.5 KEY OPPORTUNITIES
22.8 GE HEALTHCARE
22.8.1 BUSINESS OVERVIEW
22.8.2 PRODUCT OFFERINGS
22.8.3 KEY STRATEGIES
22.8.4 KEY STRENGTHS
22.8.5 KEY OPPORTUNITIES
22.9 TAMIRNA
22.9.1 BUSINESS OVERVIEW
22.9.2 MAJOR PRODUCT OFFERINGS
22.9.3 KEY STRATEGIES
22.9.4 KEY STRENGTHS
22.9.5 KEY OPPORTUNITIES
23 OTHER PROMINENT VENDORS
23.1 ACCURE THERAPEUTICS
23.1.1 BUSINESS OVERVIEW
23.2 AGILENT
23.2.1 BUSINESS OVERVIEW
23.3 ALMAC GROUP
23.3.1 BUSINESS OVERVIEW
23.4 APPLIED RESEARCH USING OMIC SCIENCES (AROMICS)
23.4.1 BUSINESS OVERVIEW
23.5 BIO-RAD LABORATORIES
23.5.1 BUSINESS OVERVIEW
23.6 BIOVISION
23.6.1 BUSINESS OVERVIEW
23.7 CARIS LIFE SCIENCES
23.7.1 BUSINESS OVERVIEW
23.8 DENOVO BIOPHARMA
23.8.1 BUSINESS OVERVIEW
23.9 DREAMGENICS
23.9.1 BUSINESS OVERVIEW
23.10 EISAI
23.10.1 BUSINESS OVERVIEW
23.11 EPIGENOMICS
23.11.1 BUSINESS OVERVIEW
23.12 IMMUNOVIA
23.12.1 BUSINESS OVERVIEW
23.13 INSILICO MEDICINE
23.13.1 BUSINESS OVERVIEW
23.14 LEXOGEN
23.14.1 BUSINESS OVERVIEW
23.15 MONUMENT TX
23.15.1 BUSINESS OVERVIEW
23.16 ORYZON GENOMICS
23.16.1 BUSINESS OVERVIEW
23.17 PLEXISION
23.17.1 BUSINESS OVERVIEW
23.18 RULES-BASED MEDICINE
23.18.1 BUSINESS OVERVIEW
23.19 SIEMENS HEALTHINEERS
23.19.1 BUSINESS OVERVIEW
23.20 SECOND GENOME THERAPEUTICS
23.20.1 BUSINESS OVERVIEW
23.21 THERMO FISHER SCIENTIFIC
23.21.1 BUSINESS OVERVIEW
23.22 YMIR GENOMICS
23.22.1 BUSINESS OVERVIEW
24 REPORT SUMMARY
24.1 KEY TAKEAWAYS
24.2 STRATEGIC RECOMMENDATIONS
25 QUANTITATIVE SUMMARY
25.1 MARKET BY GEOGRAPHY
25.2 MARKET BY INDICATION
25.3 MARKET BY APPLICATION
25.4 MARKET BY TYPE
25.5 NORTH AMERICA MARKET BY INDICATION
25.6 NORTH AMERICA MARKET BY APPLICATION
25.7 NORTH AMERICA MARKET BY TYPE
25.8 EUROPE MARKET BY INDICATION
25.9 EUROPE MARKET BY APPLICATION
25.10 EUROPE MARKET BY TYPE
25.11 APAC MARKET BY INDICATION
25.12 APAC MARKET BY APPLICATION
25.13 APAC MARKET BY TYPE
25.14 LATIN AMERICA MARKET BY INDICATION
25.15 LATIN AMERICA MARKET BY APPLICATION
25.16 LATIN AMERICA MARKET BY TYPE
25.17 MIDDLE EAST & AFRICA MARKET BY INDICATION
25.18 MIDDLE EAST & AFRICA MARKET BY APPLICATION
25.19 MIDDLE EAST & AFRICA MARKET BY TYPE
26 APPENDIX
26.1 ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
What is the current size of the global biomarkers market?
Who are the leading players in the biomarkers market?
What are the major drivers of the biomarkers market?
Which region has the highest share in the industry?
Which application segment is leading in the biomarkers industry?
Other RELATED Reports
Cell and Gene Therapy Market - Global Outlook & Forecast 2022-2027
Published : January 2022
Artificial Intelligence in Genomics Market - Global Outlook & Forecast 2022-2027
Published : February 2022